Kardigan is focusing on three patient groups: genetic dilated cardiomyopathy, moderate calcific aortic valve stenosis, and post-hospitalization acute severe hypertension. The company holds $660.7 million in liquid assets, providing a runway of about 2 to 3 years to reach important clinical milestones. Data expected in 2027 from these lead programs will be crucial for validating Kardigan's approach and guiding future investments. While optimistic about the company's prospects, caution is advised due to clinical and funding risks.
NuScale Power's Chief Financial Officer sold 20,000 shares of the company as its stock price fell by 74% over the last 12 months. This significant decline highlights challenges the company may be facing, potentially impacting investor confidence. The...
Shiba Inu's on-chain activity has increased by 42%, suggesting more transactions, but this has not yet translated into a bullish price trend. The token's price has stalled below a key resistance level around $0.0000056–$0.0000057, and momentum indica...
Ripple's stablecoin RLUSD has expanded its total supply by over 50% to $2.4 billion and increased daily transaction volumes from $200 million to $750 million since January. The company targets corporate treasurers managing $13 trillion in annual tran...
Yancoal Australia is enhancing its portfolio quality by acquiring the Kestrel metallurgical coal mine while closing the Ashton mine early. This strategy focuses on generating operational cash flow rather than reported earnings. Despite trading at a d...
Shytoshi Kusama, lead ambassador for Shiba Inu, has been silent on X since May 13, 2026, but recently updated his profile with the word "Polish," sparking speculation about upcoming developments. The term "Polish" suggests refinement or final touches...
